➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Harvard Business School
Merck
Express Scripts
McKesson
AstraZeneca

Last Updated: July 28, 2021

DrugPatentWatch Database Preview

Patents Expiring in April 2033

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Acacia BYFAVO remimazolam besylate POWDER;INTRAVENOUS 212295-001 Oct 6, 2020 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial USE OF REMIMAZOLAM FOR INDUCTION AND MAINTENANCE OF PROCEDURAL SEDATION IN ADULTS UNDERGOING PROCEDURES LASTING 30 MINUTES OR LESS
Epizyme Inc TAZVERIK tazemetostat hydrobromide TABLET;ORAL 211723-001 Jan 23, 2020 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial METHOD OF TREATING EPITHELIOID SARCOMA BY INHIBITING ENHANCER OF ZESTE HOMOLOG 2 (EZH2)
Epizyme Inc TAZVERIK tazemetostat hydrobromide TABLET;ORAL 211723-001 Jan 23, 2020 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial METHOD OF TREATING A LUNG METASTASIS OF EPITHELIOID SARCOMA
Epizyme Inc TAZVERIK tazemetostat hydrobromide TABLET;ORAL 211723-001 Jan 23, 2020 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y Y METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
Epizyme Inc TAZVERIK tazemetostat hydrobromide TABLET;ORAL 211723-001 Jan 23, 2020 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y Y METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
Epizyme Inc TAZVERIK tazemetostat hydrobromide TABLET;ORAL 211723-001 Jan 23, 2020 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION BY INHIBITING EZH2
Epizyme Inc TAZVERIK tazemetostat hydrobromide TABLET;ORAL 211723-001 Jan 23, 2020 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA BY INHIBITING EZH2
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
McKinsey
Medtronic
Johnson and Johnson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.